Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2007 | 79 | 5 | 392-398

Article title

p53 Protein in Breast Cancer - Current State of Knowledge


Title variants

Languages of publication












Physical description


1 - 5 - 2007
17 - 10 - 2007


  • Department of Surgical Oncology Chair of Oncology, Medical University, Łódź


  • Lane DP, Crawford LV: T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-63.
  • Mackay J, Steel CM, Elder PA et al.: Allele loss on short arm of chromosome 17 in breast cacer. Lancet 1988; ii: 1384-85.
  • Noble JR, Willetts KE, Mercer WE et al.: Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exper Cell Res 1992; 203: 297-304.
  • Fields S, Jang SK. Presence of potent transcription activating sequence in the p53 protein. Science 1990; 249: 1046-49.
  • Mercer WE, Shields MT, Lin D et al.: Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci USA 1991; 88: 1958-62.
  • El-Deiry WS, Tokino T, Waldman T et al.: Topological control of p21 WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910-19.
  • Lin D, Shields MT, Ullrich SJ et al.: Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci USA 1992; 89: 9210-14.
  • Lane DP: Cancer. p53, guardian of the genome. Nature 1992; 358: 15-16.
  • Reich NC, Oren M, Levine AJ: Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 1983; 3: 2143-50.
  • Momand J, Zametti GP, Olson DC et al.: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1991; 69: 1237-45.
  • Osborne RJ, Merlo GR, Mitsudomi T et al.: Mutations in the p53 gene in primary human breast cancers. Cancer Res 1991; 51: 6194-98.
  • Malkin D, Li FP, Strong LC et al.: Germ-line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 348: 747-49.
  • Srivastava S, Zou ZQ, Pirollo K et al.: Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-49.
  • Li FP, Fraumeni F Jr: Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrom. J Natl Cancer Inst 1969; 43: 1365-73.
  • Gannon JV, Greaves R, Iggo R et al.: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-1602.
  • Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93.
  • Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 1995; 66: 71-141.
  • Bánkfalvi A, Tory K, Temper M et al.: Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathol Res Pract 2000; 196: 489-501.
  • Gretarsdottir S, Tryggvadottir L, Jonasson JG et al.: TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer 1996; 74: 555-61.
  • Thirion A, Rouanet P, Thezenas S et al.: Interest of investigating p53 status in breast cancer by four different methods. Oncol Rep 2002; 9: 1167-72.
  • Thorlacius S, Thorgilsson B, Bjornsson J et al.: TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 1995; 31: 1856-61.
  • Hurlimann J, Chaubert, Benhattar J: p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol 1994; 7: 423-28.
  • Fisher CJ, Gillett CE, Vojtešek B et al.: Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 1994; 69: 26-31.
  • Wynford-Thomas D: p53 in tumor pathology: can we trust immunohistochemistry. J Pathol 1992; 166: 329-30.
  • Bessarova AV, Popov AA: Immunohistochemical detection of p53 - effect of fixation and methods of antigen retrieval. Folia Histochem Cytobiol 1998; 36: 127-32.
  • Rosen PP, Lesser ML, Arroyo CD et al.: p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995; 13: 821-30.
  • Jacobs TW, Prioleau JE, Stillman IE et al.: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996; 88: 1054-59.[Crossref][PubMed]
  • Horne GM, Anderson JJ, Tiniakos DG et al.: p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 1996; 73: 29-35.
  • Allred DC, Clark GM, Elledge R et al.: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 225-35.
  • Korsching E, Packeisen J, Agelopoulos K et al.: Cytogenetic alteration and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002; 82: 1525-33.[PubMed][Crossref]
  • Thor AD, Moore DHII, Edgerton SM et al.: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 1992; 84: 845-55.
  • Stenmark-Askmalm M, Stål O, Sullivan S et al.: Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 1994; 30A: 175-80.
  • Pietiläinen T, Lipponen P, Aaltomaa S et al.: Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 1995; 177: 225-32.
  • Luna-Moré S, de los Santos F, Breton JJ et al.: Estrogen and progesterone receptors, c-erbB-2, p53, and bcl-2 in thirty-three invasive micropapillary breast carcinomas. Path Res Pract 1996; 192: 27-32.
  • Midulla C, De Iorio P, Nagar C et al.: Immunohistochemical expression of p53, nm23-HI, Ki67, and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer. Anticancer Res 1999; 19: 4033-38.
  • Stenmark-Askmalm M, Stål O, Olsen K et al.: p53 as a prognostic factor in stage I breast cancer. Br J Cancer 1995; 72: 715-19.
  • Nakopoulou LL, Alexiadou A, Theodoropoulos GE et al.: Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol 1996; 179: 31-38.
  • Bozcuk H, Uslu G, Peætereli E et al.: Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators. Breast Cancer Res Treat 2001; 68: 239-48.[PubMed][Crossref]
  • Fresno M, Molina R, Pérez del Rio MJ et al.: p53 expression is of independent predictive value in lymph node-negative breast carcinoma. Eur J Cancer 1997; 33: 1268-74.
  • Rozan S, Vincent-Salomon A, Zafrani B et al.: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998; 79: 27-33.
  • Walker RA, Dearing SJ, Lane DP et al.: Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol 1991; 165: 203-11.
  • Kilinc N, Yaldiz M: p53, c-erbB-2 expression and steroid hormone receptors in breast carcinoma: correlations with histopathological parameters. Eur J Gynaecol Oncol 2004; 25: 606-10.
  • Paradiso A, Tommasi S, Barletta A et al.: Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients. Anticancer Res 1999; 19: 4523-28.
  • Elledge R, Clark G, Allred D: Metastatic distribution of breast cancer and survival after first recurrence, according to p53 status. 21St Annual San Antonio Breast Cancer Symposium 1998 [Abstract].
  • Caffo O, Doglioni C, Veronese S et al.: Prognostic value of p21WAF and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996; 2: 1591-99.
  • Kristen P, Müller JG, Caffier H: Prognostic relevance of p53 in node negative breast cancer. Anticancer Res 1997; 17: 2869-72.
  • Korkolis DP, Tsoli E, Yiotis J et al.: Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. Anticancer Res 2004; 24: 2061-68.
  • Barbareschi M: Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. Appl Immunohistochem 1996; 4: 106-16.
  • Dowell SP, Hall PA:. The p53 tumour suppressor gene and tumour prognosis: is there a relationship? J Pathol 1995; 177: 221-24.
  • Goldhirsch A, Glick JH, Gelber RD et al.: Meeting highlights: International Expert Consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-83.[Crossref][PubMed][WoS]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.